<DOC>
	<DOCNO>NCT02916979</DOCNO>
	<brief_summary>This study examine chemotherapy regimen immune suppressive medication set allogeneic stem cell transplant . A pilot clinical trial characterize incidence , prevalence function myeloid-derived suppressor cell ( MDSCs ) immune checkpoint regulator ( V-domain Ig Suppressor T-cell Activation [ VISTA ] , cytotoxic T-lymphocyte- associate protein 4 [ CTLA-4 ] , program death-ligand 1 [ PD-L1 ] ) early immune recovery follow allogeneic stem cell transplant . The site use myeloablative regimen fludarabine busulfan , adopt CALGB 100801 , define clinical endpoint , include engraftment , 100 day survival one year survival ( Objective # 1 ) . The site characterize incidence , prevalence function MDSCs immune checkpoint regulator patient ' blood bone marrow follow transplantation ( Objective # 2 ) . The site correlate laboratory result clinical outcome incidence graft-versus-host disease ( GVHD ) . As exploratory aim , patient experience GVHD require treatment , site define MDSCs frequency checkpoint regulator expression correlate result patient 's response GVHD therapy .</brief_summary>
	<brief_title>Myeloid-Derived Suppressor Cells Checkpoint Immune Regulators ' Expression Allogeneic SCT Using FluBuATG</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>1 . Age less equal 75 year 2 . The patient must approve transplant treat transplant physician . This include completion pretransplant workup , direct standard DartmouthHitchcock Medical Center ( DHMC ) Standard Operating Procedures ( SOPs ) . DHMC SOP Pretransplant Evaluation allogeneic recipient . 3 . The patient must disease , list , treatment responsiveness treat transplant physician believe benefit allogeneic stem cell transplant . The disease include : 1 . Acute leukemia AML ( Acute Myeloid Leukemia ) , ALL ( Acute Lymphoid Leukemia ) 2 . Chronic leukemia CML ( Chronic Myeloid Leukemia ) , CLL ( Chronic Lymphoid Leukemia ) 3 . Myelodysplasia 4 . Myelofibrosis 5 . Lymphoma NHL ( NonHodgkin 's Lymphoma ) Hodgkin 's disease 6 . Plasma cell disorder , include myeloma , Waldenstrom 's Macroglobulinemia 4 . Donor availability patient must identify donor 1 . Sibling Availability 6 6 identical donor 2 . Unrelated donor : Availability 6 6 unrelated donor 5 . No human immunodeficiency virus ( HIV ) infection active hepatitis B C 6 . Easter Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 7 . Diffusing capacity lung carbon monoxide DLCO equal 40 percent predict 8 . Left ventricular ejection fraction equal 35 percent 9 . Serum bilirubin less 2x upper limit normal transaminase less 3x normal time transplant 10 . No active uncontrollable infection 11 . In female , negative pregnancy test experience menstrual period 12 . No major organ dysfunction preclude transplantation 13 . No evidence active malignancy would limit patient 's survival le 2 year . If question , principal investigator make decision . 1 . Psychiatric disorder mental deficiency patient sufficiently severe make compliance treatment unlikely , make informed consent impossible . 2 . Major anticipated illness organ failure incompatible survival bone marrow transplant . 3 . History refractory systemic infection Donor eligibility 1 . Human leukocyte antigen ( HLA ) 6 6 match relate unrelated donor . 2 . The donor must healthy must willing serve donor , base standard guideline 3 . The donor must significant comorbidities would put donor marked increase risk 4 . There age restriction donor 5 . Informed consent must sign donor , sibling donor , third party unrelated donor . Donor Exclusion Criteria 6 . The National Marrow Donor Program ( NMDP ) guideline exclusion criterion use . In addition , follow donor NOT eligible : 7 . Syngeneic donor 8 . Pregnant lactate donor 9 . Human immunodeficiency virus ( HIV ) active HepB C donor 10 . Donor unfit receive Granulocytecolony stimulating factor ( GCSF ) undergo apheresis 11 . A donor psychiatric disorder mental deficiency make compliance procedure unlikely informed consent impossible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>